Molecular Cancer Therapeutics: 10 (10)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther October 1 2011 10 (10) 1761-1761;

Review

Review

Targeting Axl and Mer Kinases in Cancer

Anupam Verma, Steven L. Warner, Hariprasad Vankayalapati, David J. Bearss and Sunil Sharma

Mol Cancer Ther October 1 2011 10 (10) 1763-1773; DOI:10.1158/1535-7163.MCT-11-0116

Therapeutic Discovery

Therapeutic Discovery

Identification of a Natural Compound by Cell-Based Screening That Enhances Interferon Regulatory Factor-1 Activity and Causes Tumor Suppression

Jinbo Gao, Yujun Wang, Quanhua Xing, Jin Yan, Maheswari Senthil, Yasir Akmal, Claudia M. Kowolik, Julia Kang, David M. Lu, Ming Zhao, Zhixiu Lin, Christopher H.K. Cheng, M.L. Richard Yip and John H. Yim

Mol Cancer Ther October 1 2011 10 (10) 1774-1783; DOI:10.1158/1535-7163.MCT-11-0304
Therapeutic Discovery

Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells

Patrick Merle, Bertrand Evrard, Anne Petitjean, Jean-Marie Lehn, Marie-Paule Teulade-Fichou, Emmanuel Chautard, Anne De Cian, Lionel Guittat, Phong Lan Thao Tran, Jean-Louis Mergny, Pierre Verrelle and Andreï Tchirkov

Mol Cancer Ther October 1 2011 10 (10) 1784-1795; DOI:10.1158/1535-7163.MCT-10-0664
Therapeutic Discovery

Novel Irreversible Small Molecule Inhibitors of Replication Protein A Display Single-Agent Activity and Synergize with Cisplatin

Tracy M. Neher, Diane Bodenmiller, Richard W. Fitch, Shadia I. Jalal and John J. Turchi

Mol Cancer Ther October 1 2011 10 (10) 1796-1806; DOI:10.1158/1535-7163.MCT-11-0303
Therapeutic Discovery

A Novel Kinase Inhibitor of FADD Phosphorylation Chemosensitizes through the Inhibition of NF-κB

Katrina A. Schinske, Shyam Nyati, Amjad P. Khan, Terence M. Williams, Timothy D. Johnson, Brian D. Ross, Ricardo Pérez Tomás and Alnawaz Rehemtulla

Mol Cancer Ther October 1 2011 10 (10) 1807-1817; DOI:10.1158/1535-7163.MCT-11-0362
Therapeutic Discovery

A Molecular Screening Approach to Identify and Characterize Inhibitors of Glioblastoma Stem Cells

Koppany Visnyei, Hideyuki Onodera, Robert Damoiseaux, Kuniyasu Saigusa, Syuzanna Petrosyan, David De Vries, Denise Ferrari, Jonathan Saxe, Eduard H. Panosyan, Michael Masterman-Smith, Jack Mottahedeh, Kenneth A. Bradley, Jing Huang, Chiara Sabatti, Ichiro Nakano and Harley I. Kornblum

Mol Cancer Ther October 1 2011 10 (10) 1818-1828; DOI:10.1158/1535-7163.MCT-11-0268
Therapeutic Discovery

Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer

Nate N. Waldron, Dan S. Kaufman, Seunguk Oh, Zintis Inde, Melinda K. Hexum, John R. Ohlfest and Daniel A. Vallera

Mol Cancer Ther October 1 2011 10 (10) 1829-1838; DOI:10.1158/1535-7163.MCT-11-0206
Therapeutic Discovery

Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines

Venita Gresham Watson, Nicholas E. Hardison, Tyndall Harris, Alison Motsinger-Reif and Howard L. McLeod

Mol Cancer Ther October 1 2011 10 (10) 1839-1845; DOI:10.1158/1535-7163.MCT-10-0872
Therapeutic Discovery

An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B

Georg E. Winter, Uwe Rix, Andrej Lissat, Alexey Stukalov, Markus K. Müllner, Keiryn L. Bennett, Jacques Colinge, Sebastian M. Nijman, Stefan Kubicek, Heinrich Kovar, Udo Kontny and Giulio Superti-Furga

Mol Cancer Ther October 1 2011 10 (10) 1846-1856; DOI:10.1158/1535-7163.MCT-11-0100
Therapeutic Discovery

Prioritizing Candidate Disease miRNAs by Topological Features in the miRNA Target–Dysregulated Network: Case Study of Prostate Cancer

Juan Xu, Chuan-Xing Li, Jun-Ying Lv, Yong-Sheng Li, Yun Xiao, Ting-Ting Shao, Xiao Huo, Xiang Li, Yan Zou, Qing-Lian Han, Xia Li, Li-Hua Wang and Huan Ren

Mol Cancer Ther October 1 2011 10 (10) 1857-1866; DOI:10.1158/1535-7163.MCT-11-0055

Preclinical Development

Preclinical Development

NF-κB Is Required for Smac Mimetic-Mediated Sensitization of Glioblastoma Cells for γ-Irradiation–Induced Apoptosis

Rebecca Berger, Claudia Jennewein, Viola Marschall, Sabine Karl, Silvia Cristofanon, Liane Wagner, Sri HariKrishna Vellanki, Stephanie Hehlgans, Franz Rödel, Klaus-Michael Debatin, Albert C. Ludolph and Simone Fulda

Mol Cancer Ther October 1 2011 10 (10) 1867-1875; DOI:10.1158/1535-7163.MCT-11-0218
Preclinical Development

ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

Nicole Campbell, James Greenaway, Jack Henkin and Jim Petrik

Mol Cancer Ther October 1 2011 10 (10) 1876-1885; DOI:10.1158/1535-7163.MCT-11-0402
Preclinical Development

Targeting the Microtubular Network as a New Antimyeloma Strategy

Rentian Feng, Shirong Li, Caisheng Lu, Carrie Andreas, Donna B. Stolz, Markus Y. Mapara and Suzanne Lentzsch

Mol Cancer Ther October 1 2011 10 (10) 1886-1896; DOI:10.1158/1535-7163.MCT-11-0234
Preclinical Development

The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors

Giuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, Cristiana Stefan, Emmanuel Normant, Gavino Faa, Kathleen Machiels, Ulla Vanleeuw, Raf Sciot and Patrick Schöffski

Mol Cancer Ther October 1 2011 10 (10) 1897-1908; DOI:10.1158/1535-7163.MCT-11-0148
Preclinical Development

Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma

Tiffany Khong and Andrew Spencer

Mol Cancer Ther October 1 2011 10 (10) 1909-1917; DOI:10.1158/1535-7163.MCT-11-0174
Preclinical Development

Tumor-Specific Targeting of Pancreatic Cancer with Shiga Toxin B-Subunit

Matthias Maak, Ulrich Nitsche, Larissa Keller, Petra Wolf, Marianne Sarr, Marine Thiebaud, Robert Rosenberg, Rupert Langer, Jörg Kleeff, Helmut Friess, Ludger Johannes and Klaus-Peter Janssen

Mol Cancer Ther October 1 2011 10 (10) 1918-1928; DOI:10.1158/1535-7163.MCT-11-0006
Preclinical Development

CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin

Naoki Mine, Sayaka Yamamoto, Naoya Saito, Satoshi Yamazaki, Chikako Suda, Machiyo Ishigaki, Donald W. Kufe, Daniel D. Von Hoff and Takumi Kawabe

Mol Cancer Ther October 1 2011 10 (10) 1929-1938; DOI:10.1158/1535-7163.MCT-10-1139
Preclinical Development

Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents

Thapi D. Rao, Nestor Rosales and David R. Spriggs

Mol Cancer Ther October 1 2011 10 (10) 1939-1948; DOI:10.1158/1535-7163.MCT-11-0228
Preclinical Development

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O'Connor, Stephen R. Wedge and Ian J. Stratford

Mol Cancer Ther October 1 2011 10 (10) 1949-1958; DOI:10.1158/1535-7163.MCT-11-0278
Preclinical Development

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

Rachel M. Squillace, David Miller, Michelle Cookson, Scott D. Wardwell, Lauren Moran, David Clapham, Frank Wang, Tim Clackson and Victor M. Rivera

Mol Cancer Ther October 1 2011 10 (10) 1959-1968; DOI:10.1158/1535-7163.MCT-11-0273
Preclinical Development

2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin Expression

Carmine Stolfi, Roberta Caruso, Eleonora Franzè, Angelamaria Rizzo, Angela Rotondi, Ivan Monteleone, Massimo Claudio Fantini, Francesco Pallone and Giovanni Monteleone

Mol Cancer Ther October 1 2011 10 (10) 1969-1981; DOI:10.1158/1535-7163.MCT-11-0316
Preclinical Development

CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells

Boon Shing Tan, Kai Hung Tiong, Ashwin Muruhadas, Nirmal Randhawa, Heng Lungh Choo, Tracey D. Bradshaw, Malcolm F.G. Stevens and Chee-Onn Leong

Mol Cancer Ther October 1 2011 10 (10) 1982-1992; DOI:10.1158/1535-7163.MCT-11-0391

Molecular Medicine in Practice

Molecular Medicine in Practice

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Seung Tae Kim, Do Hyoung Lim, Kee-Taek Jang, Taekyu Lim, Jeeyun Lee, Yoon-La Choi, Hye-Lim Jang, Jun Ho Yi, Kyung Kee Baek, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang and Joon Oh Park

Mol Cancer Ther October 1 2011 10 (10) 1993-1999; DOI:10.1158/1535-7163.MCT-11-0269
Molecular Medicine in Practice | Free Article

BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, Linda Rolnitzky, Sharon Pelles-Avraham, Ravit Geva, Martin Edward Donach, John Curtin, Akiva Novetsky, Tal Grenader, Wei-Chu V. Lai, Alberto Gabizon, Leslie Boyd and Franco Muggia

Mol Cancer Ther October 1 2011 10 (10) 2000-2007; DOI:10.1158/1535-7163.MCT-11-0272

Main menu

User menu

Search

Table of Contents

Highlights

Review

Therapeutic Discovery

Preclinical Development

Molecular Medicine in Practice

Issue Highlights

Jump to

Articles

Info for

About MCT